Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Virtuix Signs Cooperative Research and Development Agreement with U.S. Navy
-
MediPharm Labs Reports Full Year & Fourth Quarter 2025 Results with Over 40% Annual Growth in International Medical Revenue
-
Fancamp Acquires Iron Ore Royalty and Provides Corporate Update
-
MediPharm Labs Reports Full Year & Fourth Quarter 2025 Results with Over 40% Annual Growth in International Medical Revenue
-
WISeKey’s WISeSat.Space Subsidiary Successfully Launches Its 21st Satellite to Low Earth Orbit with SpaceX
-
Elevar Therapeutics Announces FDA Acceptance for Review of New Drug Application for Lirafugratinib as Second-line Cholangiocarcinoma Treatment
-
Palvella Therapeutics Announces Scientific Publication in Journal of Vascular Anomalies Highlighting the Infiltrative Growth and Therapeutic Challenges of Microcystic Lymphatic Malformations
-
SEED Therapeutics Announces Poster Presentation at AACR Annual Meeting 2026
-
Marvel Biosciences Secures Alberta Innovates Funding to Support the Phase I Testing of MB-204
-
Drilling intersects 92.6 metres (m) of 0.95 g/t gold
-
BeyondSpring Announces Plinabulin and ADC Combination Poster Presentation at AACR Annual Meeting 2026
-
InflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Presentation at 2026 American Academy of Dermatology Annual Meeting
-
Bitfarms to Participate in Jefferies Fireside Chat
-
FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
-
Bombardier Announces Extension of Consent Solicitation with Respect to its 7.35% Debentures due 2026
-
BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9
-
BullFrog AI Announces Commercial Agreement with Top 5 Global Pharmaceutical Company to Identify and Prioritize Therapeutic Target in Major Depressive Disorder
-
Medicus Pharma Reports KOL Validation of SkinJect Phase 2 Data of 80% Overall Response Rate
-
Bicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
-
Anavex Life Sciences Provides Comprehensive Regulatory Update
-
Capitalzodiac Unveils "Geo-Matrix" – A Revolutionary Analytical Framework for the Global Strategic Minerals Sector
-
Capitalzodiac Unveils "Geo-Matrix" – A Revolutionary Analytical Framework for the Global Strategic Minerals Sector
-
NEURONES: Declaration of transactions on treasury shares (March 23 to 27, 2026)
-
Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program
-
Can-Fite’s Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026
-
Appili Therapeutics to Exhibit at World Vaccine Congress Washington
-
Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases
-
Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases
-
Bayport Management Ltd Standalone Financial Statements year ended December 2025
-
Bayport Management Ltd Group Audited Financial Statements year ended December 2025
-
Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update
-
Sight Sciences Secures Order on Post-Trial Motions That Preserves the Jury’s Verdict and Awards Monetary Damages to Sight Sciences Against Alcon and its Hydrus® Microstent
-
urban-gro, Inc. Positions for Entry into Multi-Billion-Dollar T20 Cricket Market with LPL Season Six Player Auction on May 15, 2026 via IPG Platform
-
Kraig Biocraft Laboratories Deploys Over 700,000 BAM-1 Alpha Production Hybrids, Achieving Key Milestone in its Aggressive Scale-Up Plan
-
PMGC Holdings Inc. [NASDAQ: ELAB] Reports 2025 Annual Results and Files Form 10-K, Company Expands Asset Base to $13.8M, a 43% Increase from 2024
-
Connect Biopharma Announces $20.2 Million Private Placement Financing
-
Fixing of coupon rates - Nykredit Realkredit A/S
-
Apollo Reports Results of Annual General Meeting and Appointment of New Executive Chair and Lead Director
-
Aura Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
-
Nearly 3 in 10 (29%) Gig Workers Risk Significant Penalties by Not Declaring Gig Income - Despite Regulations Requiring Gig Platforms to Report Workers’ Income to the CRA: H&R Block Canada Surve
-
49 new Nova LFS buses for the Greater Hamilton Area
-
Full Market Visibility Is Crucial for Winning Deals: What PE Firms Need to Know Now
-
BioStem Technologies Announces the Publication of its Audited Financial Statements for Fiscal Years 2024 and 2025
-
Micron Biomedical Named to Fast Company’s 2026 List of World’s Most Innovative Companies for Addressing the Most Significant Bottlenecks in How Medicine is Made, Distributed and Administered
-
Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study
-
Priority Income Fund Announces 16.6% Annualized Total Cash Distribution Rate (on Net Asset Value) with Common Shareholder Distributions for March 2026 through May 2026
-
Patent Board Upholds Seer's Nano and Micro Particle Protein Enrichment Patent in a Challenge by Bruker Subsidiaries
-
Guardian Capital Announces Changes to Certain of its Funds
-
Xali Gold Initiates Engineering and Permitting for both Operations and Exploration at Pico Machay Gold Project in Peru
-
CareCloud Highlights Successful Preferred A Conversion, Progress Toward Capital Structure Simplification, and Reaffirms Growth Outlook
